TY - JOUR
T1 - The Warburg effect and glucose-derived cancer theranostics
AU - Tekade, Rakesh K.
AU - Sun, Xiankai
N1 - Funding Information:
Rakesh K. Tekade Dr Rakesh Tekade is currently working as Assistant Professor in National Institute of Pharmaceutical Education and Research (NIPER) — Ahmedabad, Gandhinagar (India). He received his doctoral degree in pharmaceutical sciences from the Dr H.S. Gour Central University, Sagar, India (Advisor: Prof. N.K Jain). He is a recipient of several internationally acclaimed fellowships and awards: IRISH Government Postdoctoral Fellowship 2012 (Ireland); Young Scientist Award 2012 (India); Commonwealth Fellowship 2009 (Preston, UK; Advisor: Prof. Antony D’Emanuele); National Doctoral Fellowship 2008 (AICTE, India); CSIR Senior Research Fellowship 2008 (CSIR, India); and AICTE Junior Research Fellowship 2004 (AICTE, India), and to his credit has many meritorious awards. After his doctorate, he worked as postdoctoral fellows in the University of Texas Southwestern Medical Center (Dallas, USA; Supervisor: Prof. Xiankai Sun) and The University of Hawaii (Hilo, USA; Supervisor: Prof. Mahavir Chougule). Rakesh co-authored eight book chapters in international reference books and authored more than 60 publications in peer-reviewed international journals. The principal research interests of his research group mainly encompass synthesis of novel biopolymers for solubilization-targeted delivery of hydrophobes, drug/protein/siRNA/gene for cancer therapy.
Funding Information:
The authors would like to acknowledge the financial support by the Dr Jack Krohmer Professorship Funds for n ovel imaging probe development. The authors would also like to acknowledge NIPER-Ahmedabad for providing start-up financial support to Dr Tekade’s research group for his work on cancer and arthritis.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/11
Y1 - 2017/11
N2 - Tumor cells are known for their propensity to proliferate uncontrollably and generate multitudes of metastatic masses at the advanced stages of cancer. During this progression, tumor cells switch their energy source from mitochondrial oxidative phosphorylation to a glucose-dependent glycolytic pathway, despite the availability of oxygen. Consequently, tumor cells increase their metabolic rates as well as glucose uptake to maintain their proliferation. This atypical metabolic phenomenon is known as the Warburg effect, which has been recognized as a hallmark of cancer and serves as a promising target for diagnosis and therapy of cancer. In this review, we summarize the current advances toward the development of glucose-derived therapeutic and diagnostic agents (theranostics) of cancer. The Warburg effect is a well-recognized hallmark of cancer that serves as a promising target for the development of therapeutic and diagnostic (theranostic) agents for cancer. Here, we summarize the current advances in this field.
AB - Tumor cells are known for their propensity to proliferate uncontrollably and generate multitudes of metastatic masses at the advanced stages of cancer. During this progression, tumor cells switch their energy source from mitochondrial oxidative phosphorylation to a glucose-dependent glycolytic pathway, despite the availability of oxygen. Consequently, tumor cells increase their metabolic rates as well as glucose uptake to maintain their proliferation. This atypical metabolic phenomenon is known as the Warburg effect, which has been recognized as a hallmark of cancer and serves as a promising target for diagnosis and therapy of cancer. In this review, we summarize the current advances toward the development of glucose-derived therapeutic and diagnostic agents (theranostics) of cancer. The Warburg effect is a well-recognized hallmark of cancer that serves as a promising target for the development of therapeutic and diagnostic (theranostic) agents for cancer. Here, we summarize the current advances in this field.
UR - http://www.scopus.com/inward/record.url?scp=85028690598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028690598&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2017.08.003
DO - 10.1016/j.drudis.2017.08.003
M3 - Review article
C2 - 28843632
AN - SCOPUS:85028690598
SN - 1359-6446
VL - 22
SP - 1637
EP - 1653
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 11
ER -